1. Harnessing Type I IFN immunity against SARS-CoV-2 with early administration of IFN-β
- Author
-
Vinh, Dc, Abel, L, Bastard, P, Cheng, Mp, Condino-Neto, A, Gregersen, Pk, Haerynck, F, Cicalese, M, Hagin, D, Soler-Palacin, P, Planas, Am, Pujol, A, Notarangelo, Ld, Zhang, Q, H. C., S, Casanova, J, Meyts, I, Aiuti, A, Arkin, Lm, Bolze, A, Charkravorty, S, Christodoulou, J, Colobran, R, Drolet, Ba, Fellay, J, Froidure, Pa, Pape, Jw, Halwani, R, Mogensen, Th, Novelli, G, Resnick, Ib, Sediva, A, Tancevski, I, Turvey, S, Vinh, Donald C, Abel, Laurent, Bastard, Paul, Cheng, Matthew P, Condino-Neto, Antonio, Gregersen, Peter K, Haerynck, Filomeen, Cicalese, Maria-Pia, Hagin, David, Soler-Palacín, Pere, Planas, Anna M, Pujol, Aurora, Notarangelo, Luigi D, Zhang, Qian, Su, Helen C, Casanova, Jean-Laurent, and Meyts, Isabelle
- Subjects
0301 basic medicine ,2019-20 coronavirus outbreak ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunology ,Library science ,Lymphocyte Depletion ,03 medical and health sciences ,0302 clinical medicine ,Political science ,Triple combination ,Immunology and Allergy ,Animals ,Humans ,Integrative biology ,Protein Kinase Inhibitors ,COVID-19 Serotherapy ,Autoantibodies ,B-Lymphocytes ,SARS-CoV-2 ,Vaccination ,Immunization, Passive ,COVID-19 ,Immunoglobulins, Intravenous ,Interferon-beta ,Plasmapheresis ,ESTUDOS DE COORTES ,030104 developmental biology ,Infectious Diseases / Laboratory ,Settore MED/03 ,Interferon Type I ,Clinical and Translational Science Award ,Commentary ,Immunotherapy ,Translational science ,Administration (government) ,030215 immunology - Abstract
D.C.V. is supported by the Fonds de la recherche en sante du Quebec clinician-scientist scholar Junior 2 program. L.D.N. and H.C.S. are supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVID project, ANRS-COV05, the Square Foundation, Grandir - Fonds de solidarite pour l’enfance, the SCOR Corporate Foundation for Science, Institut National de la Sante et de la Recherche Medicale (INSERM), and the University of Paris. PB is supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). I.M. is a Senior Clinical Investigator at the Research Foundation – Flanders, and is chair of the CSL Behring Chair of Primary Immunodeficiencies at KU Leuven, by the KU Leuven C1 Grant C16/18/007, by a VIB GC PID Grant, by the FWO Grants G0C8517N, G0B5120N, and G0E8420N, and by the Jeffrey Modell Foundation. This work is supported by ERN-RITA.
- Published
- 2021